Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Continuous vs Intermittent Regimens in Psoriasis
2004-002629-36Phase 4Completed
- Sponsor
- Wyeth
- Start
- Dec 2004
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of etanercept in psoriasis (2 arms), sponsored by Wyeth. Primary endpoint: Mean PGA score over 54 weeks. Started Dec 2004; status: completed.
02
Drugs
etanercept
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2004-002629-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002629-36.